Abstract:Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is a tenacious pathogen that has latently infected one third of the world's population. However, conventional TB treatment regimens are no longer sufficient to tackle the growing threat of drug resistance, stimulating the development of innovative anti-tuberculosis agents, with special emphasis on new protein targets. The Mtb genome encodes ~4000 predicted proteins, among which many enzymes participate in various cellular metabolisms. For example, more than 200 proteins are involved in fatty acid biosynthesis, which assists in the construction of the cell envelope, and is closely related to the pathogenesis and resistance of mycobacteria. Here we review several essential enzymes responsible for fatty acid and nucleotide biosynthesis, cellular metabolism of lipids or amino acids, energy utilization, and metal uptake. These include InhA, MmpL3, MmaA4, PcaA, CmaA1, CmaA2, isocitrate lyases (ICLs), pantothenate synthase (PS), Lysine-ε amino transferase (LAT), LeuD, IdeR, KatG, Rv1098c, and PyrG. In addition, we summarize the role of the transcriptional regulator PhoP which may regulate the expression of more than 110 genes, and the essential biosynthesis enzyme glutamine synthetase (GlnA1). All these enzymes are either validated drug targets or promising target candidates, with drugs targeting ICLs and LAT expected to solve the problem of persistent TB infection. To better understand how anti-tuberculosis drugs act on these proteins, their structures and the structure-based drug/inhibitor designs are discussed. Overall, this investigation should provide guidance and support for current and future pharmaceutical development efforts against mycobacterial pathogenesis.

Targeting the cysteine biosynthesis pathway: Mechanism, structure, and drug discovery

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Combatting antimicrobial resistance via the cysteine biosynthesis pathway in bacterial pathogens

Inhibitors of the sulfur assimilation pathway in bacterial pathogens as enhancers of antibiotic therapy

Advancements in inhibitors of crucial enzymes in the cysteine biosynthetic pathway: Serine acetyltransferase and O-acetylserine sulfhydrylase

Exploration of Chemical Biology Approaches to Facilitate the Discovery and Development of Novel Antibiotics

Small molecules for combating multidrug-resistant superbug Candida auris infections.

Targeting Bacterial Membrane Proteins to Explore the Beneficial Effects of Natural Products: New Antibiotics against Drug Resistance

A novel antibacterial strategy for targeting bacterial methionine biosynthesis pathway

Bacterial pathogens: threat or treat (a review on bioactive natural products from bacterial pathogens)

Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens

Cave Microbes as a Potential Source of Drugs Development in the Modern Era

Structure-based Discovery of Novel Antibacterials

Targeting Bacterial Phospholipids and Their Synthesis Pathways for Antibiotic Discovery

Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Multiple antimicrobial and immune-modulating activities of cysteamine in infectious diseases

Bacterial Lipoprotein Biosynthetic Pathway As a Potential Target for Structure-based Design of Antibacterial Agents

Discovery of a New Chemical Scaffold for the Treatment of Superbug Candida Auris Infections

Ribosome‐targeting Antibacterial Agents: Advances, Challenges, and Opportunities

Ribosome-targeting antibacterial agents: Advances, challenges, and opportunities